Cipher Pharmaceuticals Inc.
TSX:CPH.TODrug Manufacturers - Specialty & Generic
+$0.15 today
- Market cap
- $331.67M
- Beta
- 0.48
- P/E (TTM)
- 9.3
- EPS (TTM)
- $1.22
Volume 0.04M
Average 0.03M
CPH.TO Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Cipher Pharmaceuticals Inc.TSX: CPH.TO
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 70.8% from a year ago
Cash & equivalents stood at $6.41M at the end of Q1 FY2026, down 70.8% from a year earlier and down 14.2% from the prior quarter. Over 3 fiscal years it compounded at -36.2% a year.
Context
- Cash & equivalents amounted to 4.2% of total assets at the end of Q1 FY2026, down 9.3 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -70.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 7.48M USD
- Year-over-year change
- -58.1%
- 4-year CAGR
- -22.3%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.48M | -58.1% |
| FY2024 | 2024-12-31 | 17.84M | -55.2% |
| FY2023 | 2023-12-31 | 39.83M | +38.1% |
| FY2022 | 2022-12-31 | 28.84M | +40.3% |
| FY2021 | 2021-12-31 | 20.55M | — |
Cash & Equivalents vs competitors
How CPH.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -70.8% is the lowest of 8, against a peer median of +33.8%.
- Cash & equivalents amounts to 4.2% of total assets for CPH.TO, versus a peer median of 18.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CA$364.68M CAD | +220.4% | -18.6% | 32.6% | |
| Mar 2026 | CA$112.48M CAD | -18.4% | -28.0% | 18.7% | |
| Mar 2026 | CA$108.05M CAD | -3.7% | +2.2% | 9.9% | |
| Mar 2026 | CA$53.94M CAD | +309.2% | — | 10.3% | |
| Mar 2026 | $40.08M USD | +76.7% | +15.6% | 55.9% | |
| Mar 2026 | $39.14M USD | +33.8% | +1.0% | 7.1% | |
| Mar 2026 | $6.41M USD | -70.8% | -36.2% | 4.2% | |
| Mar 2026 | CA$1.92M CAD | +14.9% | -21.5% | 41.9% | |
| Peer median (excluding CPH.TO) | — | +33.8% | -8.8% | 18.7% | |
Competitors are the stored peer set for CPH.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 20.55M | 28.84M | 39.83M | 17.84M | 7.48M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 6.66M | 6.8M | 5.09M | 13.86M | 11.19M |
| Inventory | 1.65M | 2.15M | 2.98M | 5.79M | 8.18M |
| Other Current Assets | 0 | 0 | 378K | 0 | 1.16M |
| Total Current Assets | 29.33M | 38.16M | 48.27M | 38.48M | 28M |
| Property, Plant & Equipment (Net) | 501K | 481K | 402K | 680K | 567.96K |
| Goodwill | 15.71M | 15.71M | 15.71M | 17.45M | 17.42M |
| Intangible Assets | 3.65M | 2.75M | 1.76M | 78.75M | 71.88M |
| Long-term Investments | 19.85M | 18.94M | 0 | 0 | 0 |
| Tax Assets | 2.47M | 16.67M | 19.89M | 26.76M | 38.12M |
| Other Non-current Assets | (19.85M) | (18.94M) | 19.89M | 386K | 235.57K |
| Total Non-current Assets | 22.32M | 35.62M | 37.76M | 124.03M | 128.22M |
| Total Assets | 51.65M | 73.78M | 86.03M | 162.51M | 156.22M |
| Account Payables | 5.56M | 4.11M | 4.64M | 5.87M | 6.38M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 6.23M | 4.9M | 0 | 54K | 0 |
| Deferred Revenue | 450K | 257K | 519K | 13.31M | 18.35M |
| Other Current Liabilities | 6.68M | 5.16M | 0 | 0 | (27.93K) |
| Total Current Liabilities | 12.29M | 9.37M | 5.25M | 19.87M | 25M |
| Long-term Debt | 0 | 0 | 0 | 40M | 4.99M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 460K | 327K | 259K | 40.3M | 5.21M |
| Total Liabilities | 12.75M | 9.7M | 5.51M | 60.17M | 30.2M |
| Common Stock | 18.12M | 17.72M | 18.01M | 27.68M | 27.81M |
| Retained Earnings | 25.2M | 50.52M | 66.27M | 77.65M | 99.93M |
| Accumulated OCI | (9.51M) | (9.51M) | (9.51M) | (9.51M) | (9.5M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 38.9M | 64.08M | 80.52M | 102.34M | 126.01M |
| Total Debt | 516K | 428K | 353K | 40.58M | 5.49M |
| Net Debt | (20.03M) | (28.41M) | (39.47M) | 22.74M | (1.98M) |
Cipher Pharmaceuticals Inc.
TSX:CPH.TO
Intrinsic Alpha fair value
Locked
Current Price
$13.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.